IP Library › Granted Patent US 12,564,722
Granted Patent B2
US 12,564,722 · App. 18/340,579 · Granted Mar 3, 2026

System and method for synchronizing energy delivery to the cardiac rhythm

Inventors: Peter Callas (Castro Valley, CA); James Lovewell (San Leandro, CA); Bradley C. Stribling (Alamo, CA); Dave Warden (Belmont, CA)
Assignee: AngioDynamics, Inc.
A61N1/3706A61N1/365A61N1/3702A61N1/327
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,564,722
App. No.
18/340,579
Granted
Mar 3, 2026
Kind
B2
Abstract

A system for synchronizing application of treatment signals with a cardiac rhythm is provided. The system includes a memory that receives and stores a synchronization signal indicating that a predetermined phase such as R-wave of a cardiac rhythm of a patient has started. A synchronization module analyzes whether the stored synchronization signal is erroneous and if so, prevents a medical treatment device from applying a treatment energy signal such as an IRE pulse to a patient to take into account an irregular heart beat and noise in the synchronization signal in order to maximize safety of the patient.

Claims (32)

1 . A system comprising:

a synchronization module operable to:

determine that a synchronization signal received from a cardiac device during a blanking period is indicative of an irregular cardiac rhythm; and

extend the blanking period in response to the determination of the irregular cardiac rhythm.

2 . The system of claim 1 , wherein the synchronization module is further operable to prevent a medical treatment device from applying a treatment signal to a patient during the extended blanking period when the synchronization signal is determined to be indicative of the irregular cardiac rhythm.

3 . The system of claim 1 , wherein the synchronization module dynamically extends the blanking period When the synchronization signal is determined to be indicative of the irregular cardiac rhythm.

4 . The system of claim 1 , wherein the synchronization module is further operable to determine that the synchronization signal received during the blanking period is erroneous.

5 . The system of claim 4 , wherein the synchronization module is further configured to prevent a medical treatment device from applying a treatment signal to a patient when the synchronization signal is determined to be erroneous.

6 . The system of claim 4 , wherein the synchronization module is operable to determine that the synchronization signal is erroneous by determining whether the blanking period was initiated within a predetermined period of time from a preceding blanking period.

7 . The system of claim 1 , wherein the synchronization module is further operable to start a new blanking period when a subsequent synchronization signal is received after the blanking period expired.

8 . The system of claim 7 , wherein the synchronization module is further operable to prevent a medical treatment device from applying a treatment signal to a patient during the new blanking period.

9 . A system for synchronizing application of treatment signals with a cardiac rhythm, the system comprising:

a memory that receives and stores a synchronization signal indicating that a predetermined phase of the cardiac rhythm of a patient has started; and

a synchronization module operable to:

determine that the synchronization signal received from a cardiac device during a blanking period is indicative of an irregular cardiac rhythm; and

extend the blanking period in response to the determination of the irregular cardiac rhythm.

10 . The system of claim 9 , wherein the synchronization module is further operable to prevent a medical treatment device from applying the treatment signals to the patient during the extended blanking period when the synchronization signal is determined to be indicative of the irregular cardiac rhythm.

11 . The system of claim 9 , wherein the synchronization module dynamically extends the blanking period when the synchronization signal is determined to be indicative of the irregular cardiac rhythm.

12 . The system of claim 9 , wherein the synchronization module is further operable to determine that the synchronization signal received during the blanking period is erroneous.

13 . The system of claim 12 , wherein the synchronization module is further configured to prevent a medical treatment device from applying the treatment signals to the patient when the synchronization signal is determined to be erroneous.

14 . The system of claim 12 , wherein the synchronization module is openable to determine that the synchronization signal is erroneous by determining whether the blanking period was initiated within a predetermined period of time from a preceding blanking period.

15 . The system of claim 12 , wherein the synchronization module is further operable to start a new blanking period when a subsequent synchronization signal is received by the memory after the blanking period expired.

16 . The system of claim 15 , wherein the synchronization module is further operable to prevent a medical treatment device from applying the treatment signals to a patient during the new blanking period.

17 . A system for synchronizing application of treatment signals with a cardiac rhythm, the system comprising:

a memory that receives and stores a synchronization signal indicating that a predetermined phase of the cardiac rhythm of a patient has started; a medical treatment device configured to apply the treatment signals to the patient; and a

synchronization module operable to:

determine that the synchronization signal received from a cardiac device during a blanking period is indicative of an irregular cardiac rhythm;

extend the blanking period in response to the determination of the irregular cardiac rhythm; and

prevent the medical treatment device from applying the treatment signals to the patient during the extended blanking period when the synchronization signal is determined to be indicative of the irregular cardiac rhythm.

18 . The system of claim 17 , wherein the medical treatment device includes an irreversible electroporation (IRE) delivery device.

19 . The system of claim 17 , wherein the medical treatment device includes a non-thermal energy delivery device.

20 . The system of claim 17 , wherein the treatment signals comprise an IRE pulse.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2023
From: CALLAS, PETER; LOVEWELL, JAMES; STRIBLING, BRADLEY C.; WARDEN, DAVE
To: ANGIODYNAMICS, INC.
Reel/Frame 064125/0136 →
Continuity (7)
Continuation 17101490 · Nov 23, 2020
Continuation 16148320 · Oct 1, 2018
Continuation 15680381 · Aug 18, 2017
Continuation 14529811 · Oct 31, 2014
Continuation 12790681 · May 28, 2010
Provisional Application 61181727 · May 28, 2009
Related Publication 20230330421A1 · Oct 19, 2023
References Cited (126)
US 5749914A · Janssen · 1998 [cited by applicant]
US 5759158A · Swanson · 1998 [cited by applicant]
US 6009647A · Feingold · 2000 [cited by applicant]
US 6010616A · Lewis · 2000 [cited by applicant]
US 6033402A · Tu · 2000 [cited by applicant]
US 6055456A · Gerber · 2000 [cited by applicant]
US 6135999A · Fanton · 2000 [cited by applicant]
US 6796981B2 · Wham · 2004 [cited by applicant]
US 7395112B2 · Keisari · 2008 [cited by applicant]
US 7871406B2 · Nields · 2011 [cited by applicant]
US 8055323B2 · Sawyer · 2011 [cited by applicant]
US 8403925B2 · Miller · 2013 [cited by applicant]
US 8670816B2 · Green · 2014 [cited by applicant]
US 9700368B2 · Callas · 2017 [cited by applicant]
US 11638603B2 · Sano · 2023 [cited by applicant]
US 11655466B2 · Neal, II · 2023 [cited by applicant]
US 11723710B2 · Neal, II · 2023 [cited by applicant]
US 11737810B2 · Davalos · 2023 [cited by applicant]
US 11890046B2 · Neal · 2024 [cited by applicant]
US 11903690B2 · Davalos · 2024 [cited by applicant]
US 11925405B2 · Davalos · 2024 [cited by applicant]
US 11950835B2 · Timothy · 2024 [cited by applicant]
US 11952568B2 · Neal, II · 2024 [cited by applicant]
US 11974800B2 · Sano · 2024 [cited by applicant]
US 12059197B2 · Davalos · 2024 [cited by applicant]
US 12173280B2 · Neal, II · 2024 [cited by applicant]
US 12214189B2 · Lorenzo · 2025 [cited by applicant]
US 12232792B2 · Neal · 2025 [cited by applicant]
US 20010043706A1 · Masuda · 2001 [cited by applicant]
US 20040116935A1 · Lechot · 2004 [cited by applicant]
US 20040237340A1 · Rembrandt · 2004 [cited by applicant]
US 20050004567A1 · Daniel · 2005 [cited by applicant]
US 20050063974A1 · Reinhard · 2005 [cited by applicant]
US 20060111705A1 · Janzen · 2006 [cited by applicant]
US 20060234752A1 · Mese · 2006 [cited by applicant]
US 20070016125A1 · Wong · 2007 [cited by applicant]
US 20070129720A1 · Demarais · 2007 [cited by applicant]
US 20070153135A1 · Han · 2007 [cited by applicant]
US 20070203537A1 · Goetz · 2007 [cited by applicant]
US 20080009102A1 · Yang · 2008 [cited by applicant]
US 20080172104A1 · Kieval · 2008 [cited by applicant]
US 20080183256A1 · Keacher · 2008 [cited by applicant]
US 20080319511A1 · Pless · 2008 [cited by applicant]
US 20090326346A1 · Kracker · 2009 [cited by applicant]
US 20100160906A1 · Jarrard · 2010 [cited by applicant]
US 20100222377A1 · Crooks · 2010 [cited by applicant]
US 20110064371A1 · Leatherman · 2011 [cited by applicant]
US 20110190851A1 · Kelly · 2011 [cited by applicant]
US 20110238057A1 · Moss · 2011 [cited by applicant]
US 20120090643A1 · Bertsch · 2012 [cited by applicant]
US 20120136347A1 · Brustad · 2012 [cited by applicant]
US 20120139734A1 · Olde · 2012 [cited by applicant]
US 20120220998A1 · Long · 2012 [cited by applicant]
US 20120265183A1 · Tulleken · 2012 [cited by applicant]
US 20120265194A1 · Podhajsky · 2012 [cited by applicant]
US 20130023871A1 · Collins · 2013 [cited by applicant]
US 20130033977A1 · Lin · 2013 [cited by applicant]
US 20130090346A1 · Johns · 2013 [cited by applicant]
US 20130110103A1 · Assmus · 2013 [cited by applicant]
US 20130296908A1 · Schulte · 2013 [cited by applicant]
US 20130338761A1 · Plowiecki · 2013 [cited by applicant]
US 20140276748A1 · Ku · 2014 [cited by applicant]
US 20150134584A1 · Nakagawa · 2015 [cited by applicant]
US 20160058493A1 · Neal, II · 2016 [cited by applicant]
US 20160143398A1 · Kim · 2016 [cited by applicant]
US 20160310203A1 · Gaspredes · 2016 [cited by applicant]
US 20160337310A1 · Faccin · 2016 [cited by applicant]
US 20170086713A1 · Pushpala · 2017 [cited by applicant]
US 20170209218A1 · Sahay · 2017 [cited by applicant]
US 20170360323A1 · Li · 2017 [cited by applicant]
US 20180028260A1 · Onik · 2018 [cited by applicant]
US 20180036529A1 · Jaroszeski · 2018 [cited by applicant]
US 20180132922A1 · Neal, II · 2018 [cited by applicant]
US 20180177543A1 · You · 2018 [cited by applicant]
US 20190023804A1 · Onik · 2019 [cited by applicant]
US 20190117964A1 · Bahrami · 2019 [cited by applicant]
US 20190223936A1 · Otten · 2019 [cited by applicant]
US 20190254736A1 · Wham · 2019 [cited by applicant]
US 20190336757A1 · Rodriguez · 2019 [cited by applicant]
US 20210162210A1 · Altmann · 2021 [cited by applicant]
US 20230000543A1 · Sano · 2023 [cited by applicant]
US 20230157759A1 · Garcia · 2023 [cited by applicant]
US 20230212551A1 · Neal, II · 2023 [cited by applicant]
US 20230248414A1 · Sano · 2023 [cited by applicant]
US 20230355293A1 · Davalos · 2023 [cited by applicant]
US 20230355968A1 · Davalos · 2023 [cited by applicant]
US 20240008911A1 · Davalos · 2024 [cited by applicant]
US 20240074804A1 · Neal · 2024 [cited by applicant]
US 20240173063A1 · Neal, II · 2024 [cited by applicant]
US 20240268878A1 · Davalos · 2024 [cited by applicant]
US 20240277245A1 · Davalos · 2024 [cited by applicant]
US 20240299076A1 · O'Brien · 2024 [cited by applicant]
US 20250000569A1 · Rafael, V · 2025 [cited by applicant]
US 20250120762A1 · Neal, II · 2025 [cited by applicant]
US 20250152230A1 · Davalos · 2025 [cited by applicant]
US 20250177741A1 · Lorenzo · 2025 [cited by applicant]
US 20250205481A1 · Davalos · 2025 [cited by applicant]
DE 833111 · 1952 [cited by applicant]
EP 0528891B1 · 2000 [cited by applicant]
EP 1061983B1 · 2004 [cited by applicant]
EP 0935482B1 · 2005 [cited by applicant]
EP 1406685B1 · 2008 [cited by applicant]
EP 1424970B1 · 2008 [cited by applicant]
JP 4252316A · 2009 [cited by applicant]
WO 2023172773A1 · 2023 [cited by applicant]
WO 2024081749A2 · 2024 [cited by applicant]
Alberts et al., “Molecular Biology of the Cell,” 3rd edition, Garland Science, New York, 1994, 1 page. [cited by applicant]
Bondarenko, A. and G. Ragoisha, Eis spectrum analyser (the program is available online at http://www.abc.chemistrybsu.by/vi/analyser/) (Accessed Aug. 28, 2020). [cited by applicant]
Korohoda, W. et al. “Reversible and Irreversible Electroporation of Cell Suspensions Flowing Through a Localized DC Electric Field”, Cellular & Molecular Biology Letters, vol. 18 (2013), pp. 102-119 (published Dec. 27, … [cited by applicant]
Latouche, E. L., M. B. Sano, M. F. Lorenzo, R. V. Davalos, and R. C. G. Martin, “Irreversible electroporation for the ablation of pancreatic malignancies: A patient-specific methodology,” J. Surg. Oncol., vol. 115, No. … [cited by applicant]
Lv, Y. et al. “The Englargement of Ablation Area by Electrolytic Irreversible Electroporation (E-IRE) Using Pulsed Field with Bias DC Field”, Annals of Biomedical Engineering, vol. 50, No. 12, Dec. 2022, 10 pages. [cited by applicant]
Mercadal, Borja et al. “Dynamics of Cell Death After Conventional IRE and H-FIRE Treatments”, Annals of Biomedical Engineering, vol. 48, No. 5, 2020, p. 1451-1462. [cited by applicant]
Neal II et al., “A Case Report on the Successful Treatment of a Large Soft-Tissue Sarcoma with Irreversible Electroporation,” Journal of Clinical Oncology, 29, pp. 1-6, 2011. [cited by applicant]
Notice of Allowance dated Jun. 21, 2024 for U.S. Appl. No. 16/938,778 (pp. 1-10). [cited by applicant]
Notice of Allowance dated Jul. 24, 2024 for U.S. Appl. No. 16/938,778 (pp. 1-2). [cited by applicant]
PCT Application No. PCT/2011/062067, International Preliminary Report on Patentability dated May 28, 2013. 7 pages. [cited by applicant]
PCT Application No. PCT/2011/066239, International Preliminary Report on Patentability dated Jun. 25, 2013. 7 pages. [cited by applicant]
PCT Application No. PCT/US15/30429, International Report on Patentability dated Nov. 15, 2016. 7 pages. [cited by applicant]
PCT Application No. PCT/US19/51731, International Preliminary Report on Patentability dated Mar. 23, 2021, 13 pages. [cited by applicant]
PCT Application No. PCT/US2010/029243, International Search Report, 4 pgs, (Jul. 30, 2010), Written Opinion, 7 pgs, (Jul. 30, 2010), and International Preliminary Report on Patentability, 8 pgs, (Oct. 4, 2011). [cited by applicant]
Pending Application No. PCT/US21/51551, International Search Report and Written Opinion dated Dec. 29, 2021, 14 pages. [cited by applicant]
Pending Application No. PCT/US23/15118, International Search Report and Written Opinion dated Jul. 31, 2023, 18 pages. [cited by applicant]
Pending Application No. PCT/US23/76626, International Search Report and Written Opinion, dated Apr. 28 17, 2024, 12 pages. [cited by applicant]
Pending Application No. PCT/US23/76626, International Search Report and Written Opinion, dated Apr. 17, 2024, 12 pages. [cited by applicant]
Reti, I. M. and Davydow, D. S., “Electroconvulsive Therapy and Antibiotics: A Case Report”, J. ECT, vol. 23, No. 4, Dec. 2007, pp. 289-290. [cited by applicant]
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies; J Galon, D Bruni; Nature reviews Drug discovery, 2019 (pp. 1-22). [cited by applicant]